Ideal induction therapy for newly diagnosed AML. Do we have a consensus?
CARDIOVASCULAR EFFECTS OF ANTHRACYCLINE-LIKE CHEMOTHERAPY AGENTS JOHN N. HAMATY FACC, FACOI.
